The revenue performance (+4.5% QoQ) was tad below the brokerage's estimates (+5.2% QoQ CC), while margins were fairly in line. The momentum within Hi-Tech and BFSI accelerated in Q4, while Healthcare growth decelerated further. Healthcare growth is expected to deteriorate even further due to Medicaid funding cut and large deals assuming support phase in FY26.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
PL Capital Report
Persistent Systems Ltd.’s unique value proposition and its strong play around regulated verticals are keeping it more resilient in this adverse environment. Additionally, the investments around hiring senior leadership team within key verticals have been instrumental in fueling client mining/hunting activities and closing large strategic deals.
We estimate USD revenues/earnings CAGR of 17%/24% over FY25-FY27E. The stock is currently trading at 38x FY27E, we are assigning P/E of 43x to FY27E with a target price of Rs 5,910 (earlier Rs 5,920).
As the stock has witnessed sharp correction in recent times; we upgrade our rating to “Buy” from earlier “Accumulate” while largely maintaining our target price.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Defence Acquisition Council Approves Rs 67,000-Crore Military-Procurement Proposals


HUL Q1 Results Review: Systematix Maintains 'Hold', Hikes Target Price — Here's Why


Suryoday SFB— Well-Positioned For A Valuation Multiple Re-Rating, Says Centrum Post Q1 Result; Maintains 'Buy'


Infosys Q1 Results Review — Motilal Oswal Maintains 'Neutral' Stance On Macro Concerns
